{"title":"Clinical Applications and Therapeutic Mechanisms of Chinese Herbal Medicine Yiaikang Capsules in Treating Acquired Immune Deficiency Syndrome.","authors":"Xue Ding, Leilei Fan, Liran Xu, Xiuxia Ma, Pengfei Meng, Jiahe Li, Jingyu Yue","doi":"10.2147/IDR.S526449","DOIUrl":null,"url":null,"abstract":"<p><p>Yiaikang (YAK) is a 22-component traditional herbal medicine, exhibiting a powerful inhibitory effect on viral replication and immunity-boosting activities in clinical applications, and is widely used to treat diseases in people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) in China. In clinical studies, YAK alleviates the clinical symptoms of HIV/AIDS (eg, weakness, shortness of breath, spontaneous sweating, and diarrhea) while enhancing quality of life and improving survival rates of patients. In the molecular mechanism studies, its main therapeutic action is inhibition of HIV replication, alongside increased numbers of CD4<sup>+</sup> T cells. These are achieved through inhibition of the viral transactivator of transcription (Tat) and regulatory protein Rev, and host intercellular adhesion molecule 1 (ICAM-1). During HIV infection, the extensive destruction of CD4+ T cells consumes the Th17 subset of intestinal-associated lymphoid tissue, resulting in the loss of mucosal integrity. YAK also restores the normal expression of C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4), promotes the proliferation of natural killer cells, regulates the balance between T helper 17 cells and regulatory T cells, and maintains the integrity of the intestinal mucosal barrier. In this review, we describe the clinical applications and therapeutic mechanisms of YAK in treating AIDS, with the goal of identifying new and efficacious therapies targets and approaches and provides new clues for the clinical application of YAK.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"3317-3327"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239890/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S526449","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Yiaikang (YAK) is a 22-component traditional herbal medicine, exhibiting a powerful inhibitory effect on viral replication and immunity-boosting activities in clinical applications, and is widely used to treat diseases in people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) in China. In clinical studies, YAK alleviates the clinical symptoms of HIV/AIDS (eg, weakness, shortness of breath, spontaneous sweating, and diarrhea) while enhancing quality of life and improving survival rates of patients. In the molecular mechanism studies, its main therapeutic action is inhibition of HIV replication, alongside increased numbers of CD4+ T cells. These are achieved through inhibition of the viral transactivator of transcription (Tat) and regulatory protein Rev, and host intercellular adhesion molecule 1 (ICAM-1). During HIV infection, the extensive destruction of CD4+ T cells consumes the Th17 subset of intestinal-associated lymphoid tissue, resulting in the loss of mucosal integrity. YAK also restores the normal expression of C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4), promotes the proliferation of natural killer cells, regulates the balance between T helper 17 cells and regulatory T cells, and maintains the integrity of the intestinal mucosal barrier. In this review, we describe the clinical applications and therapeutic mechanisms of YAK in treating AIDS, with the goal of identifying new and efficacious therapies targets and approaches and provides new clues for the clinical application of YAK.
期刊介绍:
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.